Don’t want emails from us anymore? Click here to unsubscribe.

A biotech stock is skyrocketing 70% after a breakthrough in non-opioid pain treatment, while a vaccine giant is sliding as COVID-era sales continue to fade, and a soda giant is losing its fizz with declining profits. Read on to find out more!

Profit-Driven Alerts (Sponsored)

This Free Stock Alert Could Put You Ahead of the Crowd

Apple, Microsoft, Netflix—once, they were just unknown names on a ticker.

But the investors who got in early? They saw massive gains.

Now, you have a chance to spot the next market mover before the mainstream does.

These exclusive stock alerts deliver high-potential opportunities before they hit the headlines—giving you a head start in the race for profits.

Click here to get your first alert now.

(By clicking the link above, you agree to receive emails from GuyStocks. You can opt out at any time. - Privacy Policy)

Futures 📈

What to Watch

Earnings:

Economic Reports:

Beverages

Coca-Cola Europacific 2024 Profit Down, Expects Growth in 2025

Coca-Cola Europacific Partners plc [CCEP] reported a decline in profit for fiscal 2024, despite strong revenue growth.

The beverage giant posted €1.42 billion ($1.49B) in profit attributable to shareholders, down from €1.67 billion ($1.75B) the previous year.

Earnings per share dropped to €3.08 from €3.63.

Revenue, however, climbed 11.7% year-over-year, reaching €20.44 billion ($21.4B) compared to €18.3 billion ($19.17B) in 2023.

On an adjusted comparable and FX-neutral basis, revenue grew by 3.3%.

Looking ahead, the company expects further growth in 2025. It projects a 4% revenue increase on an adjusted comparable basis and a 7% rise in operating profit.

The outlook reflects steady demand and strategic pricing adjustments.

In addition to its financial results, Coca-Cola Europacific Partners unveiled a 12-month share buyback program worth up to €1 billion ($1.05B).

The program is subject to approval at the company’s 2025 Annual General Meeting.

As one of the largest independent Coca-Cola bottlers, CCEP will continue to focus on expanding its portfolio and improving operational efficiency, despite evolving consumer preferences and global market trends.

Pharmaceuticals

Moderna Shares Plunging as COVID Vaccine Sales Continue to Slide

Moderna [MRNA] posted a larger-than-anticipated quarterly loss as the company continues to scale back manufacturing due to falling demand for its COVID-19 vaccine.

The biotechnology firm reported a fourth-quarter loss of $2.91 per share, missing analysts’ expectations of a $2.68 loss.

This marks a stark contrast from the profit of $0.55 per share recorded in the same quarter last year.

The company attributes a part of the loss to a $238 million non-cash charge tied to terminating a contract manufacturing agreement.

Chief Financial Officer James Mock stated that the decision was made to reduce excess production capacity and avoid unnecessary expenses.

Moderna's total revenue is down 66% year-over-year to $966 million, although it slightly exceeded analysts’ projections of $942.84 million.

COVID-19 vaccine sales contributed $923 million, while its respiratory syncytial virus (RSV) shot generated $15 million.

The revenue decline was primarily due to an earlier U.S. launch of the updated COVID-19 vaccine, which shifted sales into the third quarter, along with weaker international demand.

Looking ahead, the company is continuing cost-cutting efforts, aiming to reduce cash expenses by $1 billion this year and an additional $500 million in 2026.

Moderna also reaffirmed its expectation for FDA approval of its RSV vaccine for high-risk adults aged 18 to 59 later in 2025.

Shares of the firm are down around 4.5% in premarket trading, extending a nearly 60% loss in 2024.

Aerospace Market (Sponsored)

This $3 Aviation Stock Is Gaining Altitude

Just like Tesla revolutionized the roads, one company is aiming to do the same for the skies.

With breakthrough electric aviation technology, strategic industry partnerships, and a rapidly growing market presence, this company is positioned to dominate an industry projected for massive growth.

This $3 stock is still under the radar, but as the demand for clean, electric air travel takes off, this company’s upside could be enormous.

Get the full report on this potential aviation disruptor.

Energy

Portland General Electric Reports Strong Revenue Growth in 2024

Portland General Electric Company [POR] reported a significant increase in annual profit, exceeding analyst expectations.

The company’s full-year earnings are $313 million, or $3.01 per share, up from $228 million, or $2.33 per share, in the previous year.

On an adjusted basis, excluding special items, earnings are at $327 million, or $3.14 per share, slightly surpassing Wall Street projections of $3.13 per share.

Revenue for the year is up 17.7% year-over-year, reaching $3.44 billion compared to $2.92 billion in 2023.

The strong financial results reflect the company’s continued efforts to enhance its operational efficiency and expand its customer base.

Portland General Electric’s earnings growth comes amid rising energy demand and ongoing investments in infrastructure and renewable energy projects.

The company has focused on modernizing its grid and increasing reliability, which has contributed to its positive financial performance.

Looking ahead, the company remains optimistic about sustaining growth, with continued investments in sustainable energy initiatives and improvements in service delivery.

Virpax Pharmaceuticals, Inc. [VRPX] - Last Close: $0.29

Virpax Pharmaceuticals is a biopharmaceutical company focused on developing non-addictive pain management solutions and treatments for CNS disorders and antiviral barriers.

Its shares are skyrocketing 70%+ during premarket after announcing positive study results for Probudur™, a long-acting local anesthetic being developed in collaboration with the U.S. Army Institute of Surgical Research (USAISR).

Nu Skin Enterprises, Inc. [NUS] - Last Close: $6.42

Nu Skin Enterprises is a global personal care and wellness company specializing in direct sales of skincare and nutritional products.

Its shares are jumping 24% in early trade after it gave a better-than-expected Q4 earnings report, with EPS of $0.38, beating analysts' expectations of $0.22.

Roku, Inc. [ROKU] - Last Close: $86.80

Roku is a leading streaming platform. Its shares are surging in premarket after beating Q4 revenue estimates and issuing a strong 2025 revenue forecast.

Q4 revenue hit $1.20 billion, surpassing estimates of $1.15 billion. This was driven by a 25% growth in its ad-supported platform segment, which brought in $1.04 billion.

Proven Trade Setups (Sponsored)

This Breakout Trading Secret Could Give You an Edge

Trading without a clear strategy is a recipe for failure. The real winners? Traders who focus on high-probability setups.

One of the most powerful setups is the breakout trade—where price action surges past key levels, creating massive opportunities.

(By clicking the link above, you’ll receive free access to the report and a complimentary subscription to NetPicks. You also agree to the advertiser's privacy policy. Unsubscribe at any time.)

A proven breakout trading plan has been put together to help you spot, time, and execute these trades with precision and take advantage of them before the market moves.

Once you understand this method, you’ll see why it gives traders a serious advantage.

Click here to grab the report now—before the next breakout happens.

(By clicking the link above, you’ll receive free access to the report and a complimentary subscription to NetPicks. You also agree to the advertiser's privacy policy. Unsubscribe at any time.)

Everything Else

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club